Lynne Bulger has been appointed vice president, medical and clinical affairs of Cipher Pharmaceuticals, and will lead the clinical development and medical affairs efforts for current and new pipeline products.
Bulger has 27 years of experience in drug development, conducting clinical research and providing strategic medical marketing support in dermatology, rheumatology and osteoporosis. She was previously director of medical affairs at Stiefel, a GSK company; director of medical and regulatory affairs at Barrier Therapeutics; and director medical affairs at Hoffman-La Roche. Bulger also served as president of the Canadian Dermatology Industry Association from 2005 to 2008.
“We are pleased to welcome Lynne to Cipher’s management team,” said Shawn O'Brien, president and CEO of Cipher. “Her deep experience in dermatology clinical development and strong customer relationships will be valuable assets as we execute our strategy to build our dermatology pipeline, bring new products to market and support our marketing efforts.”
Additionally, Cipher promoted Peter Weiler to vice president, business development, and Linda Angaritis to vice president, global regulatory compliance and quality. Weiler has been with Cipher since 2008 and leads its expanding business development activities; Angaritis joined Cipher in 2013 and is responsible for the overall regulatory compliance and quality functions across the business.